Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06642558 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 6, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 31, 2024 to Nov 13, 2024
    • Site details revised
    v3
  3. Primary endpoints revised (14)
    • Eligibility criteria revised
    • Secondary endpoints revised (11)
    • Study description revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety and immunogenicity of two dose levels of the single dose Recombinant RSV vaccine(CHO cells), when administered intramuscularly (IM) in healthy adults aged 18 years and older.
Trial Details
NCT Number NCT06642558
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Collaborators: Henan Center for Disease Control and Prevention
Conditions
(from sponsor)		 Respiratory Syncytial Virus (RSV)
Enrollment 522 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov